作者
A Yu Helena, Camelia S Sima, Ronglai Shen, Samantha Kass, Justin Gainor, Alice Shaw, Megan Hames, Wade Iams, Jonathan Aston, Christine M Lovly, Leora Horn, Christine Lydon, Geoffrey R Oxnard, Mark G Kris, Marc Ladanyi, Gregory J Riely
发表日期
2015/3/1
期刊
Journal of thoracic oncology
卷号
10
期号
3
页码范围
431-437
出版商
Elsevier
简介
Background
We previously demonstrated that patients with metastatic KRAS mutant lung cancers have a shorter survival compared with patients with KRAS wild-type cancers. Recent reports have suggested different clinical outcomes and distinct activated signaling pathways depending on KRAS mutation subtype. To better understand the impact of KRAS mutation subtype, we analyzed data from 677 patients with KRAS mutant metastatic lung cancer.
Methods
We reviewed all patients with metastatic or recurrent lung cancers found to have KRAS mutations over a 6-year time period. We evaluated the associations among KRAS mutation type, clinical factors, and overall survival in univariate and multivariate analyses. Any significant findings were validated in an external multi-institution patient dataset.
Results
Among 677 patients with KRAS mutant lung cancers (53 at codon 13, 624 at codon 12), there was no …
学术搜索中的文章
AY Helena, CS Sima, R Shen, S Kass, J Gainor… - Journal of thoracic oncology, 2015